Immunotherapy against the Cystine/Glutamate Antiporter xCT Improves the Efficacy of APR-246 in Preclinical Breast Cancer Models

Breast cancer is the most frequent cancer in women. Despite recent clinical advances, new therapeutic approaches are still required. The cystine-glutamate antiporter xCT, encoded by the SLC7A11 gene, which imports cystine in exchange with glutamate, is a potentially new target for breast cancer ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Barutello, Giuseppina, Di Lorenzo, Antonino, Gasparetto, Alessandro, Galiazzi, Chiara, Bolli, Elisabetta, Conti, Laura, Cavallo, Federica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688020/
https://www.ncbi.nlm.nih.gov/pubmed/36359363
http://dx.doi.org/10.3390/biomedicines10112843

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688020/
https://www.ncbi.nlm.nih.gov/pubmed/36359363
http://dx.doi.org/10.3390/biomedicines10112843

Ejemplares similares